Even as Biogen and Eisai’s Leqembi and Eli Lilly’s Kisunla slowly roll out onto the market, experts question the efficacy of ...

BofA has reinstated coverage of 11 large-cap pharmaceutical and biotech stocks, with Eli Lilly (LLY), Gilead (GILD) and Merck ...

For spouses who care for a partner with Alzheimer’s disease, every day brings a different battle and a new challenge. Every ...

For spouses who care for a partner with Alzheimer’s disease, every day brings a different battle and a new challenge. Every ...

Though there is uncertainty about Biogen's sales and profits improving significantly, investors can hold the stock given the potential of its new drugs.

BofA reinstated coverage of Biogen (BIIB) with a Neutral rating and $178 price target Biogen is “a cheaper name,” mostly because Leqembi for ...

Jefferies downgraded Biogen Inc (NASDAQ:BIIB), citing the company’s tough setup. Leqembi (lecanemab) sales growth remains ...

Biogen (BIIB) was downgraded to hold by Jefferies over an anticipated royalty cut for Ocrevus, lackluster pipeline, and expected modest sales of Leqembi. Read more here.